Effect of High Flow Nasal Therapy (HFNC) Weaning Protocols vs Standard of Care on Respiratory Outcomes in Patients With Acute Respiratory Failure

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Milan

About this trial

High-flow nasal cannula (HFNC) is a widely used noninvasive respiratory support technique for patients with acute respiratory failure (ARF). It provides heated and humidified oxygen at high flow rates, improving oxygenation, reducing respiratory effort, and enhancing patient comfort. International guidelines recommend HFNC over conventional oxygen therapy in hypoxemic ARF. However, there is significant variability in clinical practice regarding HFNC discontinuation, and no standardized weaning criteria currently exist. Prolonged HFNC use may increase hospital stay and healthcare costs, while premature discontinuation may lead to respiratory deterioration and the need for further ventilatory support. Previous studies suggest that successful HFNC weaning may be predicted by a Fraction of inspired oxygen (FiO₂) ≤40% and a Respiratory rate-Oxygenation index (ROX index) ≥9.2. The ROX index is calculated as the ratio of peripheral oxygen saturation (SpO₂) divided by fraction of inspired oxygen (FiO₂) to respiratory rate. The primary objective of this study is to compare a standardized HFNC weaning strategy based on ROX index and FiO₂ thresholds with usual clinical practice based on physician judgment. The primary outcome is weaning failure at the first attempt, defined as the need for HFNC reinstitution, noninvasive or invasive mechanical ventilation, or death within 48 hours after discontinuation.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥18 years

Presence of acute respiratory failure (ARF)

Receiving HFNC treatment for ≥24 hours

Disqualifiers

Post-extubation HFNC use or tracheostomized patients

Respiratory acidosis (pH <7.35) or clinically significant acute hypercapnia (pCO₂ >50 mmHg with worsening from baseline)

Long-term home NIV or home CPAP use

Do-not-intubate (DNI) orders precluding escalation to invasive mechanical ventilation

Trial design

Design model

Parallel

Treatments tested in this trial

  • Protocolized HFNC weaning

    Other intervention

    HFNC discontinuation based on ROX index ≥9.2 and FiO₂ ≤40%

Treatment groups

148 Participants
are divided into 2 treatment groups
Group A: Non-protocolized weaningNo intervention 0 interventions
Group B: Protocolized weaningExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Weaning failure

To compare the percentage of patients who fail HFNC weaning within 48 hours after the first separation attempt using a protocolized HFNC weaning strategy based on ROX index and FiO₂ cut-offs versus standard clinical practice guided by physician judgment.

Time frame
Within 48 hours after the first separation attempt

Secondary outcomes

1

Second-attempt weaning success

To compare the percentage of patients who fail HFNC weaning within 48 hours after the second separation attempt using a protocolized HFNC weaning strategy based on ROX index and FiO₂ cut-offs versus standard clinical practice guided by physician judgment.

Time frame
Within 48 hours after the second separation attempt
2

Length of hospital stay

Comparison of total hospital stay and post-weaning hospital stay between the two study arms.

Time frame
From the day of hospital admission until the day of hospital discharge, assessed up to 60 days; and from the day of HFNC discontinuation until the day of hospital discharge, assessed up to 60 days.
3

In-hospital and 30-day mortality

Comparison of in-hospital mortality and 30-day mortality after discharge between the two study arms.

Time frame
From the day of admission to the day of discharge or death (in-hospital mortality) and from the day of admission to 30-day after discharge (30-day mortality)
4

Predictors of weaning success

Identification of clinical and respiratory variables associated with successful HFNC weaning.

Time frame
From enrollment through hospital discharge, an average of 10 days.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.